The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
A back-of-the-envelope comparison puts MariTide with a slightly better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below market ...
After 12 weeks, weight loss with the drug was 13% of body weight ... pain and physical function in the STEP 9 trial. Lilly's Zepbound has become the first drug approved by the FDA for obese ...
The drug was launched in the U.S. back in 2023 to treat obesity.